From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer

Table 1

Current and recently completed phase III trials in gastric and gastroesophageal junction cancer.

Agent	Clinical trial	Randomization		NCT identifier
HER2 inhibitors
Pertuzumab	JACOB	Pertuzumab in combination with Herceptin and chemotherapy	780	NCT01774786
T-DM1	GATSBY	T-DM1 with or without taxane.	412	NCT01641939
Trastuzumab	HELOISE	XP-T (standard versus high-dose)	400	NCT01450696
MET pathway inhibitors
Rilotumumab	RILOMET-2	XP with or without rilotumumab	450	NCT02137343
Rilotumumab	RILOMET-1	ECX with or without rilotumumab	600	NCT01697072
Onartuzumab	METGASTRIC	FOLFOX with or without onartuzumab	800	NCT01662869
Cancer stemness inhibitor
BBI608	BRIGHTER	Paclitaxel with or without BBI608	680	NCT02178956
EGFR inhibitors
Panitumumab	REAL-3	EOX with or without panitumumab	574	NCT00824785
Cetuximab	EXPAND	XP with or without cetuximab	904	NCT00678535
Angiogenesis inhibitors
Ramucirumab	REGARD	Ramucirumab versus BSC	355	NCT00917384
Ramucirumab	RAINBOW	Paclitaxel with or without ramucirumab	665	NCT01170663
Regorafenib	INTEGRATE	Regorafenib versus BSC	150	Actrn12612000239864

T-DM1: trastuzumab emtansine; XP: cisplatin, capecitabine; XP-T: cisplatin, capecitabine; T: trastuzumab; ECX: epirubicin, cisplatin, and capecitabine; FOLFOX: 5FU, folinic acid, and oxaliplatin; EOX: epirubicin, oxaliplatin, and capecitabine; BSC: best supportive care.